国际眼科纵览
國際眼科縱覽
국제안과종람
International Review of Ophthalmology
2015年
4期
274-277
,共4页
糖尿病性视网膜病变/药物治疗%新生血管形成
糖尿病性視網膜病變/藥物治療%新生血管形成
당뇨병성시망막병변/약물치료%신생혈관형성
diabetic retinopathy/medications%neovascularization
新生血管是糖尿病视网膜病变发展及预后的关键.目前已报道多种抗新生血管药物,其中部分药物如糖皮质激素、血管内皮生长因子抑制剂等已广泛应用于临床,可不同程度地抑制新生血管生成.而其他药物仍处于动物或临床试验,除血管生长抑制因子、胰岛素样生长因子结合蛋白-3可直接抑制新生血管外,富亮氨酸α-2糖蛋白-1、连接蛋白Shc均参与到新生血管生成过程,可成为抗新生血管新的治疗靶点.
新生血管是糖尿病視網膜病變髮展及預後的關鍵.目前已報道多種抗新生血管藥物,其中部分藥物如糖皮質激素、血管內皮生長因子抑製劑等已廣汎應用于臨床,可不同程度地抑製新生血管生成.而其他藥物仍處于動物或臨床試驗,除血管生長抑製因子、胰島素樣生長因子結閤蛋白-3可直接抑製新生血管外,富亮氨痠α-2糖蛋白-1、連接蛋白Shc均參與到新生血管生成過程,可成為抗新生血管新的治療靶點.
신생혈관시당뇨병시망막병변발전급예후적관건.목전이보도다충항신생혈관약물,기중부분약물여당피질격소、혈관내피생장인자억제제등이엄범응용우림상,가불동정도지억제신생혈관생성.이기타약물잉처우동물혹림상시험,제혈관생장억제인자、이도소양생장인자결합단백-3가직접억제신생혈관외,부량안산α-2당단백-1、련접단백Shc균삼여도신생혈관생성과정,가성위항신생혈관신적치료파점.
Angiogenesis is the key to the progress and prognosis of diabetic retinopathy (DR).So far,published studies have shown lots of antiangiogenic drugs.Some of these drugs,such as glucocorticoid and vascular endothelial growth factor inhibitors,has been widely applied in clinic,inhibiting neovascularization in different degrees.And the others has been still in animal or clinical trials.Besides insulin-like growth factor binding protein 3 and angiostatin controlling angiogenesis directly,leucine-rich alpha-2-glycoprotein 1 and connexin Shc could participate in the process of neovascularization,to become the new therapeutic targets of antiangiogensis.
